Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Telix Pharmaceuticals Ltd

TLX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: STRONG BUY

Last Close

$11.82

▼ -4.14%

Market Cap $8.03B · Vol 30.62K

Key Metrics

P/E Ratio

N/A

FWD: 200.71

Market Cap

$8.03B

Mid Cap

Div Yield

0.00%

N/A

EPS Growth

+223.29%

YoY

RSI (14)

76.14

Momentum

Beta

N/A

vs Market

52W High

$12.55

5.82% below

52W Low

$6.29

87.92% above

Volume

30.62K

Avg 36.54K

P/B

N/A

Price-to-book

ROE

-1.85%

Return on equity

Free Float

100.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Telix Pharmaceuticals Ltd (TLX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TLX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.60%

+7.26%

+8.84%

+80.73%

YTD

+57.81%

+7.55%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$803.79M
Net Income	$-7,125,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-1.85%
ROA · ROIC	-0.50% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	200.71
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+223.29%
Outstanding Shares	339.78M

Technical Indicators

50-Day SMA	$10.65
200-Day SMA	$9.33
RSI (14)	76.14
Beta	N/A
52-Week High	$12.55
52-Week Low	$6.29

Volume Today	30.62K
Avg Daily Volume (30D)	36.54K
Relative Volume	0.84x
Volatility (10D)	45.07
Volatility (30D)	48.10
Free Float	100.00%

Analyst Consensus

STRONG BUY

Current Price $11.82

Mean Target $19.29

52W Low$6.29 52W High$12.55

Current

Target

$6.29 $12.55

Current Analyst target

+63.21% upside potential · 10 analysts

Identifiers

ExchangeNasdaq

FIGIBBG01N69K9Y3

ISINUS87961M1053

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.